Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab

BioDrugs

Volumn 30, Issue 4, 2016, Pages 339-351

  Velayudhan, Jyoti ^a   Chen, Yuh feng ^a   Rohrbach, Amanda ^a   Pastula, Christina ^a   Maher, Gwen ^a   Thomas, Heather ^a   Brown, Ryan ^a   Born, Teresa L ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABP 501; ADALIMUMAB; BIOSIMILAR AGENT; CASPASE; FC RECEPTOR; FC RECEPTOR IA; FC RECEPTOR IIA; FC RECEPTOR IIIA; IMMUNOGLOBULIN G1 ANTIBODY; INTERLEUKIN 8; LYMPHOTOXIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; FC RECEPTOR, NEONATAL; HLA ANTIGEN CLASS 1; TUMOR NECROSIS FACTOR;

APOPTOSIS; ARTICLE; ASSOCIATION RATE CONSTANT; BINDING AFFINITY; BINDING KINETICS; BIOLOGICAL ACTIVITY; CELL DEATH; CELL MEDIATED CYTOTOXICITY; CHEMICAL STRUCTURE; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISSOCIATION RATE CONSTANT; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SCREENING; EC50; ENZYME ACTIVATION; IN VITRO STUDY; PRIORITY JOURNAL; RECEPTOR AFFINITY; RELATIVE BINDING AFFINITY; ANIMAL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CHO CELL LINE; CRICETULUS; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; SURFACE PLASMON RESONANCE;

ADALIMUMAB; ANIMALS; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; BIOSIMILAR PHARMACEUTICALS; CHO CELLS; CRICETULUS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; LYMPHOTOXIN-ALPHA; RECEPTORS, FC; RECEPTORS, IGG; SURFACE PLASMON RESONANCE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84978924417     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.1007/s40259-016-0185-2     Document Type: Article

References (32)

1. US Centers for Medicare and Medicaid Services. National health expenditures 2013 highlights. http://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/Downloads/highlights.pdf. Accessed 10 Apr 2015.
2. Zelenetz AD, Ahmed I, Braud EL, Cross JD, Davenport-Ennis N, Dickinson BD, et al. NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives. J Natl Compr Cancer Netw. 2011;9(Suppl. 4):S1–22.
3. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Scientific considerations in demonstrating biosimilarity to a reference product. Guidance for industry. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf. Accessed 12 May 2015.
4. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for industry: clinical pharmacology data to support a demonstration of biosimilarity to a reference product. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM397017.pdf. Accessed 25 Feb 2015.
5. European Medicines Agency. Guideline on similar biological medicinal products. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf. Accessed 3 Apr 2015.
6. Humira (adalimumab) injection [prescribing information]. North Chicago: AbbVie Inc.; September 1, 2015.
7. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117(2):244–79.
8. Pimentel-Muinos FX, Seed B. Regulated commitment of TNF receptor signaling: a molecular switch for death or activation. Immunity. 1999;11(6):783–93.
9. Mitoma H, Horiuchi T, Tsukamoto H, Tamimoto Y, Kimoto Y, Uchino A, et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum. 2008;58(5):1248–57.
10. Peake STC, Bernardo D, Mann ER, Al-Hassi HO, Knight SC, Hart AL. Mechanisms of action of anti-tumor necrosis factor alpha agents in Crohn’s disease. Inflamm Bowel Dis. 2013;19(7):1546–55.
11. Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov. 2009;8(3):226–34.
12. Liu J, Hutterer K, Eris T, Abel J, Jiang Y, Li C, et al. Analytical similarity assessment of a biosimilar to adalimumab. American Association of Pharmaceutical Scientists, November 2–6, 2014, San Diego, CA.
13. Feagan BG, Choquette D, Ghosh S, Gladman DD, Ho V, Meibohm B, et al. The challenge of indication extrapolation for infliximab biosimilars. Biologicals. 2014;42(4):177–83.
14. Weise M, Kurki P, Wolff-Holz E, Bielsky MC, Schneider CK. Biosimilars: the science of extrapolation. Blood. 2014;124(22):3191–6.
15. Ebbers HC. Biosimilars: in support of extrapolation of indications. J Crohns Colitis. 2014;8(5):431–5.
16. Liu J, et al. Assessing analytical similarity of proposed Amgen biosimilar ABP 501 to adalimumab. BioDrugs. doi: 10.1007/s40259-016-0184-3.
17. Arora T, Padaki R, Liu L, Hamburger AE, Ellison AR, Stevens SR, et al. Differences in binding and effector functions between classes of TNF antagonists. Cytokine. 2009;45(2):124–31.
18. Horiuchi T, Mitoma H, Harashima S, Tsukamoto H, Shimoda T. Transmembrane TNF-a: structure, function and interaction with anti-TNF agents. Rheumatology. 2010;49(7):1215–28.
19. Rosales C, Uribe-Querol E. Fc receptors: cell activators of antibody functions. Adv Biosci Biotechnol. 2013;4:21–33.
20. van der Poel CE, Spaapen RM, van de Winkel JGJ, Leusen JHW. Functional characteristics of the high affinity IgG receptor, FcgRI. J Immunol. 2011;186(5):2699–704.
21. Kohno T, Tam LT, Stevens SR, Louie JS. Binding characteristics of tumor necrosis factor receptor-Fc fusion proteins vs anti-tumor necrosis factor mAbs. J Invest Dermatol Symp Proc. 2007;12(1):5–8.
22. Santora LC, Kaymakcalan Z, Sakorafas P, Krull IS, Grant K. Characterization of noncovalent complexes of recombinant human monoclonal antibody and antigen using cation exchange, size exclusion chromatography, and BIAcore. Analyt Biochem. 2001;299(2):119–29.
23. Nesbitt A, Fossati G, Bergin M, Stephens P, Stephens S, Foulkes R, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis. 2007;13(11):1323–32.
24. Stidham RW, Lee TC, Higgins PD, Deshpande AR, Sussman DA, Singal AG, et al. Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn’s disease. Aliment Pharmacol Ther. 2014;39(12):1349–62.
25. Hazlewood GS, Rezaie A, Borman M, Panaccione R, Ghosh S, Seow CH, et al. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn’s disease: a network meta-analysis. Gastroenterology. 2015;148(2):344–54.
26. Kaur PP, Chow V, Zhang N, Moxness M, Markus R. Pharmacokinetic equivalence of ABP 501 relative to adalimumab: results from a randomized, single-blind, single-dose, parallel group study in healthy subjects [abstract]. Arthritis Rheumatol. 2014;66(10 Suppl.):S661–2.
27. Kaur P, Chow V, Zhang N, Moxness M, Markus R. A randomized, single-blind, single-dose, parallel group study in healthy subjects to demonstrate pharmacokinetic equivalence of biosimilar candidate ABP 501 and adalimumab (EU) [abstract]. Ann Rheum Dis. 2014;73(Suppl. 2):479.
28. Papp K, Strober B, Bachelez H, Costanzo A, Weglowska J, Zhang N, et al. Results from a multicenter, phase 3 study evaluating efficacy and safety of ABP 501 compared with adalimumab in subjects with moderate to severe plaque psoriasis. European Academy of Dermatology and Venerology, October 7–11, 2015, Copenhagen, Denmark.
29. Strober B, Armstrong A, Gordon K, Gottlieb A, Greenberg JD, Koo J, et al. Evaluation of efficacy and safety of ABP 501 in a phase 3 study in subjects with moderate to severe plaque psoriasis: 52-week results. American Academy of Dermatology, March 4–8, 2016, Washington DC.
30. Cohen SB, Genovese MC, Choy EH, Perez-Ruiz F, Pablos JL, Zhang N, et al. Randomized, double-blind, phase 3 study of efficacy and safety of ABP 501 compared with adalimumab in subjects with moderate to severe rheumatoid arthritis [abstract]. Arthritis Rheumatol. 2015;67(Suppl. 10):2054.
31. Matsumoto AK, Pavelka K, Rizzo W, Gupta R, Shergy W, Haycaj P, et al. Secondary efficacy endpoints: sesults from a phase 3 study comparing ABP 501 with adalimumab in subjects with moderate to severe rheumatoid arthritis [abstract]. Arthritis Rheumatol. 2015;67(Suppl. 10):2757.
32. Bandyopadhyay S, Mahajan M, Mehta T, Singh AK, Parikh A, Gupta AK. Physicochemical and functional characterization of a biosimilar adalimumab ZRC-3197. Biosimilars. 2015;5:1–18.